Search Press releases Keywords From To Category Therapy AreasAxial spondyloarthritisChronic inflammatory demyelinating polyneuropathyCrohn's diseaseEpilepsyHidradenitis suppurativaImmune ThrombocytopeniaImmune-mediated necrotizing myopathyLupusMyasthenia gravisOsteoporosisParkinson's diseaseProgressive supranuclear palsyPsoriasisPsoriatic arthritisRestless legs syndromeRheumatoid Arthritis TopicCorporateFinancialsPartnershipsPipeline progressResearch UCB MedicinesbimekizumabBriviactCimziaEvenityNayzilamNeuproVimpat 28 Jul 2022 Strong first six months – UCB with continued delivery and strong resilience Read More 20 Jul 2022 Acquisition and disposal of own shares Read More 15 Jul 2022 Acquisition and disposal of own shares Read More 9 Jul 2022 Acquisition and disposal of own shares Read More 8 Jul 2022 Acquisition and disposal of own shares Read More 6 Jul 2022 Disposal of own shares Read More Pagination First page Previous page Previous … Page 5 Page 6 Page 7 Page 8 Current page 9 Page 10 Page 11 Page 12 Page 13 … Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe